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Objectives: This study aimed to (1) compare the volumes of vastus medialis (VM), vastus lateralis (VL),
vastus intermedius and rectus femoris and the ratio of VM/VL volumes between asymptomatic controls
and patellofemoral joint osteoarthritis (PFJ OA) participants; and (2) assess the relationships between
cross-sectional area (CSA) and volumes of the VM and VL in individuals with and without PFJ OA.
Methods: Twenty-two participants with PFJ OA and 11 controls aged 40 years were recruited from the
community and practitioner referrals. Muscle volumes of individual quadriceps components were
measured from thigh magnetic resonance (MR) images. The CSA of the VM and lateralis were measured
at 10 equally distributed levels (femoral condyles to lesser femoral trochanter).
Results: PFJ OA individuals had smaller normalized VM (mean difference 0.90 cm3$kg1, a ¼ 0.011), VL
(1.50 cm3$kg1, a ¼ 0.012) and rectus femoris (0.71 cm3$kg1, a ¼ 0.009) volumes than controls. No
differences in the VM/VL ratio were observed. The CSA at the third level (controls) and fourth level (PFJ
OA) above the femoral condyles best predicted VM volume, whereas the VL volume was best predicted
by the CSA at the seventh level (controls) and sixth level (PFJ OA) above the femoral condyles.
Conclusion: Reduced quadriceps muscle volume was a feature of PFJ OA. Muscle volume could be pre-
dicted from CSA measurements at speciﬁc levels in PFJ OA patients and controls.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The patellofemoral joint (PFJ) is the compartment most
commonly affected in symptomatic knee osteoarthritis (OA)1 and is
the dominant source of symptoms associated with knee
OA2,3.Contemporary clinical guidelines recommend tailored OA
management strategies to optimize clinical outcomes, yet there is
little known about modiﬁable impairments that could guide
effective management of PFJ OA. Quadriceps weakness plays an
important role in the pathogenesis of knee OA4 and appears to be
more important in the progression of PFJ disease than tibiofemoral
joint (TFJ) disease5. Dynamometry provides an indication of the
force produced by the entire quadriceps; however, the limitations
of this technique include an inability to evaluate contributions of
the individual quadriceps subregions. This may be important for PFJ
OA, since imbalance of the medial (vastus medialis e VM) and
lateral (vastus lateralis e VL) quadriceps force may affect PFJo: K.M. Crossley, School of
y of Queensland, Brisbane,
: 61-7-3365-1877.
k.crossley@unimelb.edu.au
s Research Society International. Palignment6 and hence PFJ contact pressure7. Considering that
increased PFJ contact pressure is likely to be associated with the
initiation and progression of PFJ OA, an imbalance in the force
generating capacity of the medial and lateral vasti in people with
PFJ OA may be a potentially modiﬁable factor associated with the
development or progression of PFJ OA.
Magnetic resonance (MR) imaging is one technique that is
capable of evaluating the force generating capacity of the individual
vasti components. While measurement of muscle cross-sectional
area (CSA) from MR imaging is gaining popularity as a surrogate
measure of individual vasti muscle strength8e10, more meaningful
information may be obtained from measures of muscle volume. A
muscle’s force generating capacity, sometimes also referred to as
peak isometric muscle strength or peak isometric force11, is related
to its volume and its physiological cross sectional area (PCSA)12.
However, prior studies8e10 obtained anatomical CSAs of muscles at
various levels that may not be representative of the muscles’ PCSAs.
In a pennate muscle, the anatomical CSA does not account for angle
of muscle pennation or muscle ﬁber length and hence, may not be
a true representative of muscle force. The CSA level of a muscle that
has a strong correlation with the muscle’s volume should provide
an indication of the muscle’s strength. The CSA at this level would
provide a measurement that could be used to estimate peakublished by Elsevier Ltd. All rights reserved.
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the entire muscle volume using MR, which can be expensive and
time-consuming.
The present study aimed to (1) compare the volumes of the
individual quadriceps components (VM, VL, vastus intermedius and
rectus femoris) and the ratio of VM/VL volumes between controls
and PFJ OA participants; and (2) assess the relationships between
CSA and volumes of the VM and VL in individuals with and without
PFJ OA.
Materials and methods
Participants
Twenty-two participants with PFJ OA (symptomatic and radio-
graphic) and 11 controls (asymptomatic and no radiographic OA)
40 years of age were recruited for the study. The PFJ OA eligibility
criteria were based on a previous study protocol13. Patients were
included if they exhibited clinical symptoms arising from the PFJ
(anterior or retropatellar knee pain severity  4 on an 11-point
numerical pain scale during two PFJ loading activities: stair
ambulation, squatting and rising from sitting; aggravating activi-
ties, symptoms present on most days during the past month) and
radiographic criteria Kellgren and Lawrence (KL) grading14 applied
to the lateral PFJ 2 from skyline views3. While the PFJ OA patients
may have exhibited TFJ OA, PFJ OA patients were excluded if they
exhibited a KL grading 2 from postero-anterior views in order to
eliminate those with moderate-severe TFJ OA and hence limit our
cohort to those with predominant PFJ OA. The control participants
had no lower limb complaints, were physically active and had no
radiographic OA (KL grade 0 in all compartments). Exclusion
criteria for all participants included major surgery (including
arthroplasty or osteotomy, but not arthroscopy); knee injections
(within 3months); current or previous physiotherapy for knee pain
(within 12 months); planned lower limb surgery (following 6
months); history of hip or knee fractures; current conditions
affecting the ability to walk normally; concomitant pain from other
knee structures, hips, ankles, feet or lumbar spine; neurological or
medical conditions; ﬁbromyalgia; and contraindications for MR.
Ethics approval for the study was obtained from the University of
Melbourne Human Research Ethics Committee and the Department
of Human Services Victoria Radiation Safety committee. All
participants provided written informed consent. Age, gender,
height, body weight and body mass index (BMI) were recorded for
all subjects. The pain subscale of the Knee Injury and Osteoarthritis
Outcome Score (KOOS-pain) was used to score knee OA pain15.
Measurement of quadriceps volume
MR imaging was performed in the supine position on the most
symptomatic leg in the PFJ OA group and the dominant leg in the
control group. Both knees were fully extended to ensure uniformity
of positioning between subjects. The MR images were recorded on
a Siemens (Erlangen Germany) 3 T Trio MR scanner using a T2-
weighted fat-suppressed (water excitation) MEDIC (multi-echo
data image combination) gradient echo sequence (TE ¼ 12 ms,
TR ¼ 23 ms, NEX ¼ 1, Flip angle 12, 155 Hz/Px, Parallel imaging
GRAPPA 2) with a slice thickness of 1 mm isotropic voxels. This
sequence was chosen because it was fast and gave reasonable
delineation of muscle, cartilage and bone. The in-plane image
resolution was 397  916 pixels. The number of coronal images
ranged from 300 to 400 for each participant depending on their
height. Acquisition time was approximately 25 min per subject.
The CSAs of the VM, VL, vastus intermedius and rectus femoris
muscles were measured on axial MR images from the origin of themuscle to the insertion by manually digitizing muscle boundaries
using commercially available software (Amira 5.2, Visage Imaging,
Berlin). For each muscle, the CSAs of each axial slice were summed
and the total sum of the muscle CSAs was then multiplied by the
slice thickness to obtain the muscle volume [Fig. 1(A)]. For each
participant, the CSAs of the VM and VL were recorded at 10 evenly
spaced levels from the femoral condyles through to the lesser
trochanter [Fig. 1(B)].
The intra-rater reliability of the muscle volume measurement
techniquewas quantiﬁed in nine randomly selected subjects (ﬁve PFJ
OA; four controls). The reliability coefﬁcients obtained for VL
(ICC ¼ 0.998; 95% conﬁdence interval (CI): 0.991e1.00), VM
(ICC ¼ 0.998; 95% CI: 0.991e1.00), vastus intermedius
(ICC ¼ 0.997; 95% CI: 0.987e0.999) and rectus femoris
(ICC ¼ 0.994; 95% CI: 0.975e0.999) indicate excellent repeatability
of the measures. Accordingly, the standard error of measurement
(SEM) was acceptably low (VL 0.10 cm3$kg1; VM 0.06 cm3$kg1;
vastus intermedius 0.14 cm3$kg1; rectus femoris 0.05 cm3$kg1).
Statistical analysis
All data were analyzed with the Statistical Package for the Social
Sciences (PASW Statistics 18, SPSS Inc., Chicago, IL) and a < 0.05.
Between-group differences in participant characteristics were
assessed using independent t-tests or chi square tests as appro-
priate. The ratio of VM/VL muscle volume was calculated for both
the control and PFJ OA groups. To control for the inﬂuence of body
weight and gender, muscle volumes (cm3$kg1) were normalized
to body weight and all between-group comparisons of muscle
volumes were performed using an Analysis of Covariance (with and
without gender as a covariate). Radiographic disease severity and
knee pain are also potential confounders, and the univariate asso-
ciation of radiographic disease severity of the PFJ (measured with
the KL grading system14) and the KOOS-pain subscale with the
individual muscle volumes was determined using the Spearman’s
rho correlation coefﬁcient. Regression analyses were performed on
the 10 equally-spaced CSAs (from the femoral condyles to lesser
trochanter of the femur) of VM and VL to determine the CSA that
best predicted the muscle volume in the control and PFJ OA groups.
To evaluate whether dominance inﬂuenced vasti muscle size, the
CSA that best represented the medial and lateral vasti was also
calculated for the non-dominant leg of the control group, and these
were compared to the dominant leg using a paired t-test.
Results
Participant and disease characteristics
The control group (n ¼ 11; age 53  5 years, body weight
71  14 kg, BMI 25  3 kg$m2) and the PFJ OA group (n ¼ 22; age
57 11 years, weight 77 13 kg, BMI 274 kg$m2) werematched
for all participant characteristics (P > 0.05). There were more
females than males in both groups (female: male ratios in the
control and PFJ OA groups were 7:4 and 15:7, respectively), with no
difference in the frequencies (c2 ¼ 0.546; P-value ¼ 0.07). No
association was observed between muscle volumes and PFJ radio-
graphic disease severity (VM: rs ¼ 0.291; P ¼ 0.189; VL:
rs ¼ 0.156; P ¼ 0.487; VM/VL ratio: rs ¼ 0.202; P ¼ 0.367), or
KOOS-pain (VM: rs ¼ 0.135; P ¼ 0.550; VL: rs ¼ 0.119; P ¼ 0.598;
VM/VL ratio: rs ¼ 0.212; P ¼ 0.344).
Between-group comparison of quadriceps volume
Individuals with PFJ OA had smaller normalizedmuscle volumes
of VM (mean difference 0.90 cm3$kg1, 95% CI [0.22e1.57];
Fig. 1. (A) Delineation of the VM (yellow), VL (green), vastus intermedius (orange) and
rectus femoris (purple) on axial MR images, where (1) represents segmented and
unsegmented proximal axial MR image, (2) represents segmented and unsegmented
mid thigh axial MR image and (3) represents segmented and unsegmented distal axial
MR image. (B) CSAs of the VM and VL were obtained at 10 evenly spaced levels from
the femoral condyles to the lesser trochanter of the femur (dashed lines). The solid
black lines identify the levels that were the strongest predictors of muscle volume for
the controls, whereas the solid gray lines identify the levels that were the strongest
predictors of muscle volume for the PFJ OA participants.
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femoris (0.71 cm3$kg1 [0.19e1.22; a ¼ 0.009) than controls
(Table I). No differences were observed in vastus intermedius
(0.56 cm3$kg1 [0.59 to 1.71]; a ¼ 0.331). These results were
reﬂected in peak isometric muscle strength comparisons (see
Supplementary Material). The ratio of VM/VL muscle volumes in
the PFJ OA group (0.66  0.08) and the control group (0.64  0.06)
were not different (0.27 [0.50; 1.05]; a ¼ 0.47).
Relationship between VM and lateralis volumes and CSAs
For the VM, regression modeling revealed that the CSA at the
third level (r2¼ 0.936; B¼ 17; a< 0.001) and fourth level above the
femoral condyles (r2 ¼ 0.668; B ¼ 18; a < 0.001) were the best
predictors ofmuscle volume in the controls and PFJ OA participants,
respectively. For the VL, muscle volumewas predicted by the CSA at
the seventh level above the femoral condyles (r2 ¼ 0.916; B ¼ 26;
a < 0.001) in the controls, and at the sixth level above the femoral
condyles (r2 ¼ 0.705; B ¼ 17; a < 0.001) in the PFJ OA participants.
These levels generally represented the largest CSA for each muscle.
Comparison of muscle size between dominant and non-dominant
limbs
For the VM, the CSA at the third level of the dominant leg
(20 6 cm2) was not signiﬁcantly different from the non-dominant
leg (21  7 cm2); P ¼ 0.161. Similarly, for the VL there was no
signiﬁcant difference between the CSA at the seventh level for the
dominant leg (28 5 cm2) and the non-dominant leg (27 6 cm2);
P ¼ 0.184.
Discussion
The volumes of the VM and VL, normalized to bodyweight, were
signiﬁcantly smaller in the PFJ OA group (approximately 20%) than
the control group. However, we found no difference in the ratio of
VM/VL volumes between those with and without PFJ OA. In both
the PFJ OA and the control group, the ratio of VM/VL was approx-
imately 0.67, indicating that the VM volumewas approximately 2/3
that of the VL in both groups. Based on the evidence from cadaveric
and modeling studies, indicating that imbalance of the medial and
lateral vasti contributes to heightened lateral PFJ stress16,17, we
considered that there may have been a lower ratio of VM/VL
volumes in those with PFJ OA. Our ﬁnding of no difference in the
VM/VL ratio implies that the force generating capacity of the VM is
not affected to a greater extent than that of the VL in our population
with PFJ OA.
While we did not observe between-group differences in the
relative muscle volume between the two heads of the vasti, it is
possible that altered coordination and activation of the VM andTable I
Averaged muscle volumes of the quadriceps for the PFJ OA and control groups.
Muscle volume andmuscle volume normalized to subject mass are given, alongwith
standard deviations (SD). Signiﬁcant differences (P < 0.05) in normalized muscle
volume between the PFJ OA subjects and control subjects are indicated
Muscle Muscle volume
(SD) (cm3)
Normalized muscle
volume (SD) (cm3/kg)
VL PFJ OA 453.1 (173.2) P ¼ 0.012 5.8 (1.6)
Control 505.1 (202.7) 7.3 (1.4)
VM PFJ OA 292.9 (100.9) P ¼ 0.011 3.7 (0.9)
Control 325.2 (129.3) 4.6 (0.9)
Vastus intermedius PFJ OA 397.4 (173.7) 5.0 (1.6)
Control 418.3 (191.4) 5.6 (1.3)
Rectus femoris PFJ OA 177.9 (71.3) P ¼ 0.009 2.3 (0.7)
Control 206.7 (81.1) 3.0 (0.7)
H.F. Hart et al. / Osteoarthritis and Cartilage 20 (2012) 863e868866lateralis may exist in those with PFJ OA. Indeed, modeling studies
have identiﬁed that delayed activation of the medial quadriceps
(relative to the lateral quadriceps) increases lateral patellar mala-
lignment18,19, leading to areas of heightened contact pressure
across the lateral PFJ16,17. However, it is also possible that our
ﬁndings may be more aligned with studies that did not observe
differences in the onset timing of the medial and lateral vasti
between those with and without generalized knee OA20e22. While
the current study cannot be compared to those studies that have
investigated temporal aspects of the vasti activations in peoplewith
generalized knee OA, further investigation is required to establish
whether the imbalances in activations of the vasti muscles,
observed in younger people with patellofemoral pain23,24, are also
a feature of PFJ OA.
The ﬁnding of lower size in three of the four quadriceps in the
PFJ OA group reﬂects previous reports of association between
reduced quadriceps strength and PFJ OA5,25. Muscle weakness is
inﬂuenced by muscle atrophy and the capacity to fully activate the
muscle4. Hence, our ﬁndings suggest that VM, VL and rectus fem-
oris atrophy may be a feature of PFJ OA and likely contribute to
torque deﬁcits observed in these individuals. Smaller quadriceps
muscles may have reduced capacity to absorb shock26 or provide
integrated sensorimotor function to the knee joint27, thus
rendering the joint more susceptible to damage28. Furthermore,
results from a longitudinal cohort study5 and an animal model28
indicate that the PFJ is more susceptible to joint degeneration
than the TFJ in the presence of lower quadriceps strength. Due to
the cross-sectional nature of our research design it is not possible to
determinewhether the pain and structural changes associatedwith
PFJ OA leads to muscle disuse and atrophy, or whether reduced
muscle activity contributes to PFJ OA onset. However, our ﬁndings
indicate that a program designed to improve strength in the VM
and VL, in addition to the rectus femoris, may beneﬁt thosewith PFJ
OA. However, such programs could also overload the PFJ29, with
potential to increase pain; thus, progression of load should be
carefully managed. Further studies are required to conﬁrmwhether
quadriceps strengthening could reduce symptoms or disease
progression in people with PFJ OA.
We used MR imaging to quantify muscle size, which expanded
on previous studies that evaluated the strength of the quadriceps
when represented as one whole muscle-tendon unit. Since our
study did not detect any imbalance in the relative contributions of
the medial and lateral vasti, it is not clear whether measurement of
the sizes of the individual quadriceps subregions provides greater
value than overall quadriceps strength measures obtained from
dynamometry. Furthermore, MR imaging of the entire thigh is
expensive and the segmenting of muscle volumes is time-
consuming. However, dynamometry is not readily available in the
clinical setting, and this instrumentation is expensive to purchase.
Our results indicate that CSAs of the VM and VL (at speciﬁed levels)
may provide a valid indication of muscle size for those clinicians
and researchers without access to dynamometry.
Our study highlights that the VM CSA at approximately 8 cm
(control) and 12 cm (PFJ OA) above the femoral condyles were the
best predictors of VM volume, while VL CSA at approximately 24 cm
(control) and 20 cm (PFJ OA) best predicted VL volume. The gross
anatomies of the two muscles are quite distinct, which was
reﬂected in the disparate levels that best represent the corre-
sponding muscle volume. Indeed, these levels generally represent
the largest CSA for each individual vastus. However, previous
studies have described vasti CSA at a single level, with distances
ranging from 3.8 cm8,9 to 15 cm10 superior to the proximal patella
pole, which may not represent the muscle volumes and force
capacities of these muscles. These studies ought to consider the
speciﬁc CSA of the muscle that is most representative of themuscle’s volume, in addition to controlling for the effects of gender
and body weight.
In the current study, we investigated muscle size for the indi-
vidual quadriceps components in people with and without symp-
tomatic radiographic PFJ OA. The quantiﬁcation of muscle volume
used in the current study provides a better estimate of the force
generating capacity of the muscles than measuring anatomical
CSAs, which may not be representative of the muscle’s PCSA. Our
calculations of muscle volume, PCSA and peak isometric force
values in the control group (Table I and Supplementary Table) were
in reasonable agreement with those in the literature30e32. For
example, our average muscle volume and PCSA of the controls for
VL (505.1 cm3 and 80.7 cm2, respectively) were of similar magni-
tudes to those of Friedrich and Brand (1990) (514.0 cm3 and
64.4 cm2, respectively)31, while our average muscle volume and
PCSA of rectus femoris (206.7 cm3 and 32.9 cm2, respectively)
compare favorably to data reported by Klein Horsman et al. (2007)
(226.3 cm3 and 28.9 cm2, respectively)30.
There are a number of limitations of our study that should be
considered. The MR images were performed under non-weight
bearing conditions at full knee extension, which is standard
protocol for clinical imaging of the knee; however, it is not known
whether the results would have been the same if a weight-bearing
activity (involving quadriceps activation) was simulated. While
these limitations may have inﬂuenced the calculations of muscle
volume, they are unlikely to have affected the between-group
comparisons. The use of the dominant leg to calculate muscle
volume in the control group and themost symptomatic leg in the PFJ
OA may have resulted in bias. However, we performed some
preliminary analyses to conﬁrm that the CSA for VM and VLwere not
different between legs in the control group. Therefore, it is unlikely
that meaningful between-leg differences in the control group would
have affected our between-group comparisons. A further limitation
is the lack of detailed MR data, from which to score additional
features of OA. For example, the radiographs cannot reveal features
such as cartilage or bone marrow lesions, synovitis or effusion.
Therefore, we cannot rule out that some participants in the control
group may have had signs of OA that were not detectable on
radiographs. However, currently radiographic deﬁnitions of OA
remain the gold standard, and we can be conﬁdent that our control
group was free of radiographically detected OA.
It is also acknowledged that neuromuscular factors contribute to
a muscle’s strength and that the strength and size of other antag-
onistic or synergistic muscles also inﬂuence the load on the PF joint,
and therefore may be important for people with PFJ OA. Finally, the
cross-sectional nature of the study design precludes any conclu-
sions regarding the temporal relationship between muscle size and
PFJ OA. Longitudinal studies are required to ascertain the role of
quadriceps muscle size in the etiology and progression of PFJ OA.Conclusion
There was no difference in the ratio of VM/VL volumes between
thosewith andwithout PFJ OA. The volumes of the VM, VL and rectus
femoris, normalized to bodyweight,were approximately 20% smaller
in the PFJ OA than the control group. Further studies are required to
ascertain whether imbalance in the activations of the VM and later-
alis is a feature of PFJ OA, and whether quadriceps strengthening can
reduce symptoms or disease progression in people with PFJ OA.Author contributions
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